Comparative Pharmacology
Head-to-head clinical analysis: ICLUSIG versus QINLOCK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ICLUSIG versus QINLOCK.
ICLUSIG vs QINLOCK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ponatinib is a multi-targeted tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant form, and also inhibits VEGFR, PDGFR, FGFR, EPH receptors, and SRC family kinases.
Ripretinib is a switch-control tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor alpha (PDGFRA) kinase signaling. It binds to both the switch pocket and the activation loop of KIT and PDGFRA, preventing kinase activation and inhibiting downstream signaling pathways involved in tumor cell proliferation and survival.
45 mg orally once daily with or without food.
150 mg orally once daily with food, until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is approximately 7.5 hours in healthy subjects, supporting twice-daily dosing.
Terminal elimination half-life is approximately 15 hours (range 11–20 hours) in patients with advanced GIST. This supports twice-daily dosing.
Primarily fecal (91%) as unchanged drug and metabolites; renal elimination accounts for less than 4% of the dose.
Primarily hepatic metabolism, with <1% excreted unchanged in urine. Fecal excretion accounts for approximately 80% of the administered dose, with renal excretion of unchanged drug being minimal (<1%).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor